Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Kevin Kalinsky, Ingrid A. Mayer et al.|New England Journal of Medicine|2019Cited by 846
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*David M. Goldenberg, Robert M. Sharkey|Oncotarget|2015Cited by 464
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Linda T. Vahdat, Jennifer R. Diamond et al.|Journal of Clinical Oncology|2017Cited by 407
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Wells A. Messersmith et al.|Annals of Oncology|2021Cited by 371
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid TumorsAlexander Starodub, David M. Goldenberg, Allyson J. Ocean et al.|Clinical Cancer Research|2015Cited by 344